DepoCyt® (cytarabine liposome injection) is indicated for
the intrathecal treatment of lymphomatous meningitis.
DOSAGE AND ADMINISTRATION
Preparation And Administration Precautions
DepoCyt is a cytotoxic anticancer drug and, as with other
potentially toxic compounds, caution should be used in handling DepoCyt. The
use of gloves is recommended. If DepoCyt suspension contacts the skin, wash
immediately with soap and water. If it contacts mucous membranes, flush
thoroughly with water.
Preparation And Administration
No further reconstitution or dilution is required.
DepoCyt particles have a tendency to settle with time. Vials of DepoCyt should
be allowed to warm to room temperature and gently agitated or inverted to re-suspend
the particles immediately prior to withdrawal from the vial. Avoid aggressive
DepoCyt should be withdrawn from the vial immediately
before administration. DepoCyt is a single dose vial and does not contain any
preservative. DepoCyt should be used within 4 hours of withdrawal from the
vial. Unused portions of each vial should be discarded properly [see HOW
SUPPLIED/ Storage and Handling]. Do not save any unused portions for
later administration. Do not mix DepoCyt with any other medications.
In-line filters must not be used when administering
DepoCyt. DepoCyt is administered directly into the cerebrospinal fluid (CSF)
via an intraventricular reservoir or by direct injection into the lumbar sac.
DepoCyt should be injected slowly over a period of 1-5 minutes. Following drug
administration by lumbar puncture, the patient should be instructed to lie flat
for 1 hour. Patients should be observed by the physician for immediate toxic
For the treatment of lymphomatous meningitis, DepoCyt 50
mg (one vial of DepoCyt) is recommended to be given according to the following
||DepoCyt, 50 mg, administered intrathecally (intraventricular or lumbar puncture) every 14 days for 2 doses (weeks 1 and 3).
||DepoCyt, 50 mg, administered intrathecally (intraventricular or lumbar puncture) every 14 days for 3 doses (weeks 5, 7 and 9) followed by 1 additional dose at week 13.
||DepoCyt, 50 mg, administered intrathecally (intraventricular or lumbar puncture) every 28 days for 4 doses (weeks 17, 21, 25 and 29).
Patients should be started on dexamethasone 4 mg twice a
day either by mouth or intravenously for 5 days beginning on the day of DepoCyt
If drug related neurotoxicity develops, the dose should
be reduced to 25 mg. If it persists, treatment with DepoCyt should be
Dosage Forms And Strengths
Ready-to-use, single dose vial containing 50 mg/5 mL (10
mg/mL) of cytarabine liposome injection.
Storage And Handling
DepoCyt® (cytarabine liposome injection) is supplied as a
sterile, white to off-white suspension in 5 mL glass, single dose vials.
Store refrigerated at 2° to 8°C (36° to 46°F). Protect
from freezing and avoid aggressive agitation.
Available in individual carton containing one ready to
use vial. NDC 57665-331-01.
Do not use beyond expiration date printed on the label.
DepoCyt is a genotoxic drug. Follow special handling and
disposal procedures [see REFERENCES].
OSHA Hazardous Drugs. OSHA. [Accessed on November 4,
2014, from http://www.osha.gov/SLTC/hazardousdrugs/index.html].
Manufactured by: Pacira Pharmaceuticals, Inc., San Diego,
CA 92121. Distributed by: Sigma-Tau Pharmaceuticals, Inc., Gaithersburg, MD